2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1398

Comparison Of Atherogenicity Of Plasma From Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Abstract Number: 109

Comparison Of Characteristics In Rheumatoid Arthritis Between International and National Databases In Europe: A Systematic Literature Review
Abstract Number: 1577

Comparison Of Clinical and Serological Manifestations Among Juvenile-, Adult-, and Late-Onset Systemic Lupus Erythematosus Patients In Korea
Abstract Number: 1451

Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable In The United States
Abstract Number: 1019

Comparison Of Comorbidity Indexes In a Clinical and Administrative Rheumatoid Arthritis Cohort: A Case For The Rheumatic Diseases Comorbidity Index
Abstract Number: 2049

Comparison Of Corticosteroid Plus Lidocaine Or Lidocaine Alone In Patients Receiving Celecoxib For The Treatment Of Acute Shoulder Or Trochanteric Bursitis: A Randomized, Double-Blind, Placebo Controlled Trial
Abstract Number: 1906

Comparison Of Decision Rules For Identifying Patients With Systemic Lupus Erythematosus (SLE) In Administrative Healthcare Databases
Abstract Number: 2622

Comparison Of Different Methods Of Skin Pathergy Test In Patients With Behçet’s Syndrome
Abstract Number: 1449

Comparison Of Effects Of Standard- and Low-Dose Etanercept On Inflammatory Synovitis In Rheumatoid Arthritis Patients As Assessed By Ultrasonography
Abstract Number: 1042

Comparison Of Medication Usage Following Myocardial Infarction In Patients With Autoimmune Rheumatic Disease Versus Controls
Abstract Number: 2372

Comparison Of Proposed Biosimilar PF-05280586 With Rituximab: Nonclinical and Phase I Clinical Assessments
Abstract Number: 2068

Comparison Of Radioimmunoprecipitation Versus Antigen Specific Assays For Identification Of Myositis Specific Autoantibodies In Dermatomyositis Patients
Abstract Number: 1262

Comparison Of Remission Rates For Pediatric Membranous Plus Proliferative Lupus Nephritis Versus Isolated Proliferative Lupus Nephritis: An Analysis Of The Childhood Arthritis and Rheumatism Research Alliance Registry
Abstract Number: 1945

Comparison Of Selected Joint Evaluation With Comprehensive Assessment In Musculoskeletal Ultrasonography For Detection Of Synovitis In Rheumatoid Arthritis
Abstract Number: 1455

Comparison Of Serum Matrix Metalloproteinase-3 Levels In Rheumatoid Arthritis After Treatment With Adalimumub Or Abatacept For 24 Weeks

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].